touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
touchMDT for touchONCOLOGY
What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)?
Listen to experts Dr Lizza Hendriks and Prof. Suresh Senan discuss the rationale for using ICIs in LS-SCLC, including relevant evidence from clinical trials in extended-stage SCLC and LS-SCLC, and review the novel and emerging late-phase ICIs for LS-SCLC.
The multidisciplinary team:
Pulmonologist – Dr Lizza Hendriks,
Maastricht University Medical Center, Maastricht, The Netherlands
Radiation oncologist – Prof. Suresh Senan
Amsterdam University…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.